Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) has a Wall Street consensus price target of $33.00, based on estimates from 16 covering analysts. With the stock currently trading at $23.08, this represents a potential upside of +43.0%. The company has a market capitalization of $2.83B.
Analyst price targets range from a low of $33.00 to a high of $33.00, representing a 0% spread in expectations. The median target of $33.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CPRX trades at a trailing P/E of 13.7x and forward P/E of 12.4x. The forward PEG ratio of 0.66 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +10.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $36.23, with bear and bull scenarios of $-3760.29 and $50.65 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CPRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CPRX is $33, representing 43.0% upside from the current price of $23.08. With 16 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CPRX has a consensus rating of "Buy" based on 16 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $33 implies 43.0% upside from current levels.
With a forward P/E of 12.3641x, CPRX trades at a relatively low valuation. The consensus target of $33 implies 43.0% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $33 for CPRX, while the most conservative target is $33. The consensus of $33 represents the median expectation. Our quantitative valuation model projects a bull case target of $51 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CPRX is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CPRX stock forecast based on 16 Wall Street analysts shows a consensus price target of $33, with estimates ranging from $33 (bear case) to $33 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $36, with bear/bull scenarios of $-3760/$51.
Our quantitative valuation model calculates CPRX's fair value at $36 (base case), with a bear case of $-3760 and bull case of $51. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.
CPRX trades at a forward P/E ratio of 12.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 13.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on CPRX, with a "Buy" consensus rating and $33 price target (43.0% upside). 15 of 16 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CPRX analyst price targets range from $33 to $33, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33 consensus represents the middle ground. Our model's $-3760-$51 range provides an independent fundamental perspective.